Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

6 May 2009 16:04

RNS Number : 8008R
ViaLogy PLC
06 May 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY SEEKS NEW PARTNER TO COMMERCIALIZE BURIED PIPELINE IMAGING

LondonMay 6, 2009ViaLogy (LSE:VIY) ViaLogy PLC today confirmed that it is actively seeking a new partner for the final proof-of-concept stage of QSUB™, the technology application it is developing for detecting underground oil and gas pipelines, utilities and other significant buried objects.  Using patented Quantum Resonance Interferometry (QRI™) software, QSUB interprets multiple synthetic aperture radar (SAR) sets obtained by aerial survey. 

In proof-of-concept tests carried out in OregonUnited States of AmericaViaLogy was able to exploit ground disturbances to infer a buried pipeline.  Subsequent digging revealed a six inch asbestos pipe buried 6 to 12 feet below the ground.  Based on archival search reports, the pipe was buried over four decades ago.  This test also provided ViaLogy with new opportunities for imaging and geolocation of buried utilities and pipelines via detection of ground disturbance, that are typically outside the scope of conventional SAR processing.  In addition, confirmatory tests showed that ViaLogy detected over 150 'hidden' metal objects and wires at various depths.

"The need for a new strategic partner has occurred because our initial associate, Advanced Spatial Technologies Field Services (ASTFS), has ceased operating," said Terry Bond, chairman of ViaLogy.  "This is unfortunate because the complete success of our initial tests is most encouraging and the addressable market for such a product remains significant."

"Now we need to conduct additional flights over varying terrain using the very latest aerial radar to collect sophisticated data.  We will then be able to refine QSUB to provide a much-needed operational service to the oil and gas industry.  This final step requires adequate development funding, hence the need for a new partner. This process is underway.

Commenting on ViaLogy's other involvement in the energy sector, QuantumRD™ which interprets seismic data for the location and analysis of oil well sites, Mr Bond said: "I have just returned from Texas where our technology has enabled our partners there, Atascosa Exploration LLC, to drill two successful wells on the Galba Fuqua Prospect, near San Antonio." 

"We have now contracted to analyse seismic data for a third, larger well for Atascosa and had detailed discussions about further projects. We have also received several enquiries from other exploration companies in the US and Europe."

For further information please contact:

ViaLogy PLC

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUUUPUAUPBGAQ
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.